These inhibitors demonstrated the ability to suppress CHD1L-mediated TCF/LEF transcriptional activity, reverse EMT, and reduce cancer stem cell (CSC) stemness in colorectal cancer models, mirroring the effects observed with CHD1L knockdown. Here, CHD1L is linked to cancer.